Printer Friendly

WIRB-Copernicus Group Acquires Clinical Research Technology Firms MedAvante and ProPhase.

M2 EQUITYBITES-May 11, 2017-WIRB-Copernicus Group Acquires Clinical Research Technology Firms MedAvante and ProPhase


11 May 2017 - US-based clinical services organisation provider WIRB-Copernicus Group (WCG) has acquired data services company MedAvante and clinical trials measurement specialist ProPhase, the firm said.

WIRB-Copernicus has named Jeffrey Litwin as the CEO of the combined organisation.

The acquisition of MedAvante and ProPhase positions WCG in the growing central nervous system and behavioural health assessment markets through the delivery of clinical services and technology solutions that improve signal detection.

With these two firms added into the family of companies, WCG said it will provide clients a more comprehensive and integrated suite of study start-up solutions.

Financial details about the transaction were not disclosed.

WIRB-Copernicus works for biopharmaceutical companies, CROs and institutions.

MedAvante is a clinical science-driven data services company focused on maximising signal detection in global clinical trials.

With Virgil, its electronic clinical outcome assessment platform, clinical research sponsors are able to maximise outcome data quality and increase operational efficiency for clinical trials across multiple therapeutic areas.

MedAvante built the first electronic source (eSource) data platform and has conducted more than 687,000 assessments of 56,000 clinical trial subjects across 233,000 study visits.

The company's eSource data has been accepted by both the Food and Drug Administration and the European Medicines Agency in successful regulatory submissions.

ProPhase is a global provider of measurement-related specialty solutions in clinical trials.

For over a decade, ProPhase has focused on applying innovation to optimise the selection, use, and analysis of behavioural endpoints to mitigate trial risk and maximise the likelihood of study success.

ProPhase specialises in the development of new outcome measures, calibration of real world outcomes, placebo response mitigation, and prediction of treatment adherence.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:May 11, 2017
Previous Article:New Albany Park condominiums first NEP Innovation Gateway program customer.
Next Article:UL Acquires Canadian Building Science and Building Envelope Service Provider CLEB.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters